Peripheral blood lymphocytes incubated with tumour cells or extracts may undergo blastogenesis. This is the basis of a technique studied in children with acute lymphoblastic leukaemia (ALL) in childhood in an attempt to predict relapse. Samples of peripheral blood and bone marrow from 82 children with varying degrees of ALL were analysed. Cultures were prepared by incubating a lymphocyte suspension with an autologous bone-marrow suspension. Final ratios of lymphocytes to bone-marrow cells (L : BM) were 1: 1 and 2: 1. Control wells received bone-marrow or lymphocyte suspension only. Cultures were incubated for 72, 96, and 120 hours. All were pulse-labelled with 3H-TdR and radioactivity was measured by scintillation counting. Results were expressed as the stimulation index, calculated by dividing the mean counts per minute (cpm) of wells containing both lymphocytes and bone-marrow cells by the sum of the mean cpm for control wells. If the stimulation index exceeded 1 at 72, 96, or 120 hours at either L: BM ratio a positive response was recorded.
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(Accepted 35January 1978) Immunological detection of residual leukaemic disease in the bone marrow of children with acute lymphoblastic leukaemia SHANT Summary and conclusions Peripheral blood lymphocytes incubated with tumour cells or extracts may undergo blastogenesis. This is the basis of a technique studied in children with acute lymphoblastic leukaemia (ALL) in childhood in an attempt to predict relapse. Samples of peripheral blood and bone marrow from 82 children with varying degrees of ALL were analysed. Cultures were prepared by incubating a lymphocyte suspension with an autologous bone-marrow suspension. Final ratios of lymphocytes to bone-marrow cells (L : BM) were 1: 1 and 2: 1. Control wells received bone-marrow or lymphocyte suspension only. Cultures were incubated for 72, 96, and 120 hours. All were pulse-labelled with 3H-TdR and radioactivity was measured by scintillation counting. Results were expressed as the stimulation index, calculated by dividing the mean counts per minute (cpm) of wells containing both lymphocytes and bone-marrow cells by the sum of the mean cpm for control wells. If the stimulation index exceeded 1 at 72, 96, or 120 hours at either L: BM ratio a positive response was recorded.
Seventy-six children were in clinical remission at the time of testing (group A) and six were in clinical relapse (group B and relapsed later at a mean time of 3-8 months (21 with marrow disease, two with testicular infiltration, and one with lung infiltration). Sixteen patients showed stimulation and had up to 4% blasts in their bone marrow but remained in remission. Nineteen other patients showed a positive response and several factors may have contributed to this: two underwent a "rebound" lymphocytosis after stopping treatment, nine had current or intercurrent infections, two had persistent unexplained bone-marrow lymphocytosis, but six had no causative symptoms and thus their responses were "true falsepositives." Seventeen patients from group A showed no response and remained in remission for a mean of 22-9 months after testing. None of the six children in group B responded, and at testing had 17-85% blasts in their bone marrow.
During the study no patient relapsed who had not shown a positive response. The technique merits further study as a guide to the presence of leukaemic cells. 
Introduction

Results
The ability of autologous peripheral-blood lymphocytes to respond to autologous bone-marrow cells was influenced by the L: BM ratio and period of incubation in the 35 patients who were studied at both ratios and all three incubation times (table I). The mean stimulation index for 72, 96, and 120 hours at an L : BM ratio of 1: 1 was 2 74 compared with 2 33 at a ratio of 2: 1 (P <001). At both ratios extending the incubation period resulted in an increased rate of response and a proportional increase in the stimulation index. Six of the 35 patients showed no response at either ratio or any incubation time: 16 children responded at all ratios and incubation times; and 13 children responded at one or more of the ratios and incubation times. In contrast to the 24 children in responding group Al, 17 patients (non-responding group Al) showed a negative reaction and remained in remission for a mean of 22-9 months after testing. These patients had been in remission for 17 9 months before testing.
Only six of the 82 children studied were in clinical relapse at the time of testing (group B). None of them responded. The proportion of blasts in these children ranged from 170 to 85 %. The negative results may have been due to antigen excess or to impaired cellular responses. To find the minimum percentage of relapse blasts needed to stimulate autologous peripheral blood lymphocytes, blasts were separated from bone-marrow samples from two patients in relapse and stored in liquid nitrogen in a freezing medium containing 10 % dimethyl sulphoxide. After remission had been induced with cytotoxic drugs (both patients had had at least 87 % blasts in their bone marrow) lymphocytes were collected from the peripheral blood and cultured in the presence of varying concentrations of stored autologous relapse blasts. The minimum percentage of blasts needed to produce a blastogenic response (stimulation index 1) was found to be 0-7 ± SE 0 3 in one case and 1 21 +0 4 in the other.
Discussion
These results show that peripheral-blood lymphocytes from patients with ALL in remission can be stimulated by autologous bone-marrow cells. The mechanism of the stimulatory response is uncertain, but it is probably directed against antigens associated with leukaemic blasts that may not be detectable on routine haematology. Increasing evidence suggests that membranebound antigenic determinants are present on leukaemic cells but not on normal cells.6-9 The blastogenic response in our patients in remission was either associated with a few blasts (up to 4%) in the bone marrow or was quickly followed by relapse (mean time 3-8 months).
The bone marrow of all the 24 children who relapsed during the study (responding group Al) produced appreciable stimulation of peripheral-blood lymphocytes. Thus during the past 24 months we have seen no child whose response could be classified as false-negative-that is, one who had not responded before relapsing. The difference between the disease-free period of the 24 responding patients (table II) and the 17 children whose lymphocytes failed to respond to stimulation (non-responding group Al) was highly significant (P <0-001). Gutterman et al'0 cultured autologous blood lymphocytes with bone-marrow cells from 25 adults with acute leukaemia in remission. Out of 17 patients whose peripheral-blood lymphocytes failed to react to autologous bone-marrow cells, 15 remained in complete remission (median time 10 5 months); but five of the remaining eight patients whose lymphocytes were stimulated by the bonemarrow cells subsequently relapsed (median time 6-5 months). The difference in relapse rates between these two groups was also significant.
The failure of peripheral-blood lymphocytes to be stimulated by bone-marrow cells in the group of 17 non-responding children is easily explained by the long and continuous absence of leukaemic cells in the marrow. Two reasons might explain the non-stimulation of lymphocytes from children who were in relapse when the in-vitro test was performed. Firstly, some blasts from the bone marrow may have escaped into the circulation causing an antigen excess or blocking effect so that the addition of blasts did not have any blastogenic influence. Secondly, the cellular responses of children with ALL are extremely low when in relapse but return to normal immediately after induction of remission." 12 We have not tested the ability of lymphocytes from patients in relapse to respond to other antigens.
Bone-marrow samples from six of the 17 non-responding children, who continued in complete clinical remission for an average of 23 months, were tested at regular intervals. All of the 26 repeat tests on these long-term survivors failed to induce blastogenesis of autologous peripheral-blood lymphocytes. This correlation between a lack of response and absence of leukaemic blasts suggests that a negative result in the in-vitro test is a good prognostic sign. Nevertheless, a blastogenic response among patients in remission does not necessarily indicate the presence of leukaemic blasts, nor is it a certain sign of ensuing relapse, since in our study 13 children who responded had no signs of malignant disease but had symptoms such as infections, lymphocytosis, and "rebound" effect. Other primary and secondary haematological disorders may also produce a positive response, but as such studies are limited for ethical reasons no healthy controls have yet been examined.
Interestingly, three asymptomatic patients with no excess of marrow blasts showed a positive response to testing. Biopsy specimens from other than the routine sites (namely, bone marrow and CSF) showed leukaemic infiltrates (cases 21-23-table III). In one patient a lung biopsy was performed for the diagnosis of nodular lung disease and histological examination showed leukaemic cells. Testicular biopsy specimens from two other boys also contained leukaemic cells. In another patient (table 111-case 12), who had recurrent bone pain, the bone marrow showed relapse at one site, though other sites were normal. Marrow samples taken from two other sites over a prolonged period were normal."3 Bone-marrow cells from these three apparently normal aspirates produced stimulation of autologous peripheral-blood lymphocytes.
Patients in apparent clinical remission may have a few leukaemic cells in extramedullary sites.'4 Simple bone-marrow aspiration may not provide enough evidence of a disease-free state and patients with a positive blastogenic response may still be harbouring leukaemic cells and hence be in danger of ultimate relapse. A positive response may be relevant to the issue of whether to stop or continue treatment or to add extra treatment such as testicular irradiation.
